CN120208923A - Lnp023的结晶形式 - Google Patents

Lnp023的结晶形式 Download PDF

Info

Publication number
CN120208923A
CN120208923A CN202510371145.0A CN202510371145A CN120208923A CN 120208923 A CN120208923 A CN 120208923A CN 202510371145 A CN202510371145 A CN 202510371145A CN 120208923 A CN120208923 A CN 120208923A
Authority
CN
China
Prior art keywords
lnp023
crystalline monohydrate
monohydrate form
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510371145.0A
Other languages
English (en)
Chinese (zh)
Inventor
贾子辰
P·卢斯滕贝格尔
M·迈尔
M·莫拉托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN120208923A publication Critical patent/CN120208923A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202510371145.0A 2020-05-18 2021-05-17 Lnp023的结晶形式 Pending CN120208923A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063026637P 2020-05-18 2020-05-18
US63/026,637 2020-05-18
US202063052699P 2020-07-16 2020-07-16
US63/052,699 2020-07-16
CN202180035091.0A CN115667240B (zh) 2020-05-18 2021-05-17 Lnp023的结晶形式
PCT/IB2021/054225 WO2021234544A1 (en) 2020-05-18 2021-05-17 Crystalline form of lnp023

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202180035091.0A Division CN115667240B (zh) 2020-05-18 2021-05-17 Lnp023的结晶形式

Publications (1)

Publication Number Publication Date
CN120208923A true CN120208923A (zh) 2025-06-27

Family

ID=76076387

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202510371145.0A Pending CN120208923A (zh) 2020-05-18 2021-05-17 Lnp023的结晶形式
CN202510350702.0A Pending CN120168469A (zh) 2020-05-18 2021-05-17 Lnp023的结晶形式
CN202510349446.3A Pending CN120172955A (zh) 2020-05-18 2021-05-17 Lnp023的结晶形式
CN202180035091.0A Active CN115667240B (zh) 2020-05-18 2021-05-17 Lnp023的结晶形式

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202510350702.0A Pending CN120168469A (zh) 2020-05-18 2021-05-17 Lnp023的结晶形式
CN202510349446.3A Pending CN120172955A (zh) 2020-05-18 2021-05-17 Lnp023的结晶形式
CN202180035091.0A Active CN115667240B (zh) 2020-05-18 2021-05-17 Lnp023的结晶形式

Country Status (10)

Country Link
US (3) US11603363B2 (https=)
EP (1) EP4153580A1 (https=)
JP (3) JP7592743B2 (https=)
KR (2) KR20230009478A (https=)
CN (4) CN120208923A (https=)
AU (2) AU2021276912B2 (https=)
CA (1) CA3180829A1 (https=)
IL (1) IL297975A (https=)
TW (2) TWI858258B (https=)
WO (1) WO2021234544A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS66635B1 (sr) 2017-08-31 2025-04-30 Novartis Ag Derivati piperidinil-indola za upotrebu u lečenju c3 glomerulopatije
CN120208923A (zh) * 2020-05-18 2025-06-27 诺华股份有限公司 Lnp023的结晶形式
US11951101B2 (en) 2020-07-16 2024-04-09 Novartis Ag Methods of using factor B inhibitors
AU2021414253B2 (en) * 2020-12-30 2024-05-16 Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. Series of piperidine-substituted benzoic acid compounds, and use thereof
MX2023013148A (es) * 2021-05-07 2023-11-28 Novartis Ag Iptacopan para el tratamiento del sindrome uremico hemolitico atipico.
JP2024522769A (ja) 2021-06-18 2024-06-21 ノバルティス アーゲー 自己免疫性血液学的疾患を治療する方法
IL314494A (en) 2022-03-04 2024-09-01 Novartis Ag Use of iptacopan for the treatment of lupus nephritis
JP7849520B2 (ja) * 2022-06-30 2026-04-21 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 含窒素架橋複素環誘導体の薬学的に許容される塩、結晶形及びその調製方法
WO2024176169A1 (en) 2023-02-23 2024-08-29 Novartis Ag Methods of using factor b inhibitors
TW202508580A (zh) 2023-08-25 2025-03-01 瑞士商諾華公司 使用因子b抑制劑之方法
WO2025148628A1 (zh) * 2024-01-10 2025-07-17 河北以岭医药研究院有限公司 哌啶基吲哚衍生物及其制备方法和应用
TW202533829A (zh) 2024-02-16 2025-09-01 瑞士商諾華公司 用於治療anca相關性血管炎的因子b抑制劑
WO2026003809A1 (en) * 2024-06-29 2026-01-02 Assia Chemical Industries Ltd. Solid state forms of iptacopan hydrochloride

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
KR20130086534A (ko) * 2010-06-01 2013-08-02 플러스 케미칼스, 에스.에이. 익사베필론의 고체 형태
JO3425B1 (ar) * 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
KR20180091097A (ko) 2015-12-23 2018-08-14 그리노파티온 바이오테크 게엠베하 보체 활성화를 억제하기 위한 폴리펩티드
RS66635B1 (sr) 2017-08-31 2025-04-30 Novartis Ag Derivati piperidinil-indola za upotrebu u lečenju c3 glomerulopatije
CN120208923A (zh) * 2020-05-18 2025-06-27 诺华股份有限公司 Lnp023的结晶形式

Also Published As

Publication number Publication date
WO2021234544A1 (en) 2021-11-25
CN120172955A (zh) 2025-06-20
US20230265067A1 (en) 2023-08-24
AU2021276912B2 (en) 2023-12-14
JP2026048795A (ja) 2026-03-17
US20250270186A1 (en) 2025-08-28
AU2024201640B2 (en) 2025-10-09
JP2023518552A (ja) 2023-05-02
KR20230009478A (ko) 2023-01-17
US11603363B2 (en) 2023-03-14
EP4153580A1 (en) 2023-03-29
KR20250048392A (ko) 2025-04-08
JP7592743B2 (ja) 2024-12-02
JP2024150466A (ja) 2024-10-23
CN115667240A (zh) 2023-01-31
TW202204335A (zh) 2022-02-01
IL297975A (en) 2023-01-01
JP7789850B2 (ja) 2025-12-22
TWI858258B (zh) 2024-10-11
US20210371394A1 (en) 2021-12-02
US12384758B2 (en) 2025-08-12
CA3180829A1 (en) 2021-11-25
TW202504893A (zh) 2025-02-01
AU2024201640A1 (en) 2024-04-04
CN115667240B (zh) 2025-04-22
CN120168469A (zh) 2025-06-20
AU2021276912A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
CN115667240B (zh) Lnp023的结晶形式
US20250188054A1 (en) Crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
US12590095B2 (en) Crystalline forms of an orally available, selective kit and PDGFR kinase inhibitor
RU2818684C1 (ru) Кристаллическая форма lnp023
CN110582279B (zh) 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶，其制备方法和药物组合物
JP6594325B2 (ja) 臭化チオトロピウムとラクトースの結晶形態
JP2018515477A (ja) 免疫調節薬の新規な結晶形
HK40127061A (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
HK40065390B (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
HK40065390A (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination